Stocktoria
Cue Biopharma, Inc. CUE
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2018-01-02
Chart by TradingView
5/9
Piotroski F — financial health
-27.27
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Revenue | $27.5M | $9.3M | $5.5M | $1.2M | $14.9M |
| Operating income | -$26.6M | -$41.5M | -$52.1M | -$53.2M | -$43.7M |
| Net income | -$26.6M | -$40.7M | -$50.7M | -$53.0M | -$44.2M |
| Operating cash flow | -$21.7M | -$36.3M | -$40.0M | -$41.8M | -$38.8M |
| Free cash flow | -$21.9M | -$36.4M | -$40.0M | -$42.0M | -$39.8M |
| Total assets | $42.2M | $32.2M | $61.5M | $91.3M | $83.4M |
| Total liabilities | $15.8M | $14.7M | $24.4M | $25.6M | $17.9M |
| Shareholders' equity | $26.4M | $17.5M | $37.1M | $65.7M | $65.5M |
| Ratios | |||||
| Operating margin | -96.7% | -446.9% | -949.9% | -4275.1% | -292.6% |
| Net margin | -96.9% | -438.0% | -924.1% | -4257.8% | -295.6% |
| FCF margin | -79.6% | -391.9% | -727.9% | -3371.6% | -266.0% |
| Return on assets | -63.0% | -126.4% | -82.5% | -58.1% | -53.0% |
| Return on equity | -100.6% | -232.4% | -136.8% | -80.7% | -67.4% |
| Debt / equity | — | 0.00× | 0.11× | 0.12× | 0.00× |
| Current ratio | 2.74 | 1.84 | 3.01 | 6.68 | 5.35 |
| Revenue growth | 195.7% | 69.2% | 341.0% | -91.7% | 373.7% |
Why these scores methodology →
Piotroski F-score: 5/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -27.27 (distress)
- Working capital / assets 0.556
- Retained earnings / assets -8.729
- EBIT / assets -0.629
- Equity / liabilities 1.675
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001645460 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.